CD19 and B-cell chronic lymphocytic leukemia: Shortly after that, another clinical trial on chronic lymphocytic leukemia (CLL) demonstrated durable and effective responses to lentiviral FMC63(CD19)/4-1BB/CD3ζ CAR-T treatment, reported by the University of Pennsylvania, Philadelphia [186].